On Visit To Japan, Sanofi’s Viehbacher Weighs In On Innovation Models, Clinical Trial Transparency
This article was originally published in PharmAsia News
Executive Summary
Increased funding and public-private interaction in a new research “control tower” would be welcomed by industry in Japan, Viehbacher said. But the CEO told PharmAsia News that he opposes expanded regulatory oversight on clinical trial transparency.